Ronald Wayne Takvorian, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vidarabine | 4 | 2024 | 345 | 0.470 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2024 | 1596 | 0.380 |
Why?
|
Lymphoma | 4 | 2023 | 1877 | 0.380 |
Why?
|
Neurotoxicity Syndromes | 2 | 2023 | 290 | 0.300 |
Why?
|
Hodgkin Disease | 4 | 2019 | 1415 | 0.220 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 11524 | 0.200 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2023 | 233 | 0.190 |
Why?
|
Adenine | 2 | 2024 | 936 | 0.190 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 3 | 2015 | 180 | 0.190 |
Why?
|
Vinblastine | 2 | 2019 | 502 | 0.170 |
Why?
|
Cyclophosphamide | 3 | 2024 | 2242 | 0.170 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 1378 | 0.160 |
Why?
|
Leukemia, Hairy Cell | 1 | 2018 | 82 | 0.160 |
Why?
|
Piperidines | 2 | 2024 | 1602 | 0.160 |
Why?
|
Immunotherapy, Adoptive | 3 | 2023 | 1270 | 0.150 |
Why?
|
Pancytopenia | 1 | 2018 | 104 | 0.150 |
Why?
|
Doxorubicin | 3 | 2019 | 2234 | 0.140 |
Why?
|
Dacarbazine | 1 | 2019 | 566 | 0.140 |
Why?
|
Central Nervous System Neoplasms | 1 | 2023 | 895 | 0.130 |
Why?
|
Splenic Neoplasms | 1 | 2015 | 100 | 0.120 |
Why?
|
Arabinonucleosides | 1 | 2013 | 35 | 0.110 |
Why?
|
Adenine Nucleotides | 1 | 2013 | 121 | 0.110 |
Why?
|
Mediastinal Neoplasms | 1 | 2013 | 423 | 0.090 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2019 | 1381 | 0.090 |
Why?
|
Remission Induction | 4 | 2019 | 2386 | 0.080 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2013 | 640 | 0.080 |
Why?
|
Pyrazoles | 1 | 2019 | 1972 | 0.080 |
Why?
|
Pyrimidines | 1 | 2019 | 2942 | 0.070 |
Why?
|
Lymphoma, B-Cell | 1 | 2013 | 931 | 0.070 |
Why?
|
Stem Cell Transplantation | 1 | 2015 | 1620 | 0.070 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5442 | 0.070 |
Why?
|
Central Nervous System | 2 | 2023 | 1357 | 0.070 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 3 | 2015 | 693 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2019 | 5535 | 0.050 |
Why?
|
Lung Neoplasms | 2 | 2005 | 13102 | 0.050 |
Why?
|
Lymphoma, Follicular | 1 | 2005 | 435 | 0.050 |
Why?
|
Treatment Outcome | 8 | 2024 | 63114 | 0.050 |
Why?
|
Neoplasm Staging | 4 | 2013 | 11031 | 0.050 |
Why?
|
Follow-Up Studies | 5 | 2024 | 39050 | 0.050 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2005 | 1770 | 0.050 |
Why?
|
Survival Analysis | 2 | 2019 | 10252 | 0.040 |
Why?
|
Disease-Free Survival | 4 | 2015 | 6895 | 0.040 |
Why?
|
Transplantation, Autologous | 1 | 2023 | 2124 | 0.040 |
Why?
|
Administration, Oral | 2 | 2019 | 3913 | 0.040 |
Why?
|
Middle Aged | 14 | 2023 | 213383 | 0.040 |
Why?
|
Adult | 13 | 2023 | 214055 | 0.040 |
Why?
|
Thyroid Neoplasms | 1 | 2011 | 2282 | 0.040 |
Why?
|
Epistaxis | 1 | 2018 | 111 | 0.040 |
Why?
|
Erythema | 1 | 2018 | 257 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2005 | 3479 | 0.040 |
Why?
|
Humans | 22 | 2024 | 744343 | 0.040 |
Why?
|
Prognosis | 3 | 2023 | 29063 | 0.030 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2019 | 659 | 0.030 |
Why?
|
Forearm | 1 | 2018 | 409 | 0.030 |
Why?
|
Aged | 10 | 2019 | 163280 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2015 | 5686 | 0.030 |
Why?
|
Hematologic Diseases | 1 | 2019 | 498 | 0.030 |
Why?
|
Nitrogen Mustard Compounds | 1 | 2015 | 45 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2023 | 2016 | 0.030 |
Why?
|
Busulfan | 1 | 2015 | 263 | 0.030 |
Why?
|
Radiography | 1 | 2005 | 7023 | 0.030 |
Why?
|
Male | 13 | 2019 | 350118 | 0.030 |
Why?
|
Aged, 80 and over | 5 | 2013 | 57776 | 0.030 |
Why?
|
Retrospective Studies | 4 | 2023 | 77449 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2023 | 2645 | 0.030 |
Why?
|
Sulfonamides | 1 | 2022 | 1938 | 0.030 |
Why?
|
Spleen | 1 | 2018 | 2362 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 1978 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2023 | 3778 | 0.030 |
Why?
|
Female | 13 | 2019 | 380194 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2009 | 9274 | 0.030 |
Why?
|
Tacrolimus | 1 | 2015 | 743 | 0.020 |
Why?
|
Vincristine | 1 | 2013 | 1039 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4933 | 0.020 |
Why?
|
Survival Rate | 3 | 2015 | 12788 | 0.020 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 1519 | 0.020 |
Why?
|
Young Adult | 4 | 2019 | 56430 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 2015 | 11366 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 2948 | 0.020 |
Why?
|
Prednisone | 1 | 2013 | 1574 | 0.020 |
Why?
|
Methotrexate | 1 | 2015 | 1727 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2459 | 0.020 |
Why?
|
Sirolimus | 1 | 2015 | 1564 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2618 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2011 | 1950 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1915 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2011 | 826 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2013 | 2559 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2214 | 0.020 |
Why?
|
Liver Neoplasms | 2 | 2019 | 4253 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2023 | 10180 | 0.020 |
Why?
|
Lymphoproliferative Disorders | 1 | 2009 | 523 | 0.020 |
Why?
|
Ultrasonography | 1 | 2018 | 5985 | 0.020 |
Why?
|
Technetium Tc 99m Aggregated Albumin | 1 | 1984 | 67 | 0.020 |
Why?
|
Prospective Studies | 3 | 2022 | 53288 | 0.020 |
Why?
|
Digestive System | 1 | 1984 | 253 | 0.010 |
Why?
|
Pain | 1 | 2018 | 4986 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2018 | 12959 | 0.010 |
Why?
|
Hepatic Artery | 2 | 1984 | 245 | 0.010 |
Why?
|
Biopsy | 1 | 2015 | 6756 | 0.010 |
Why?
|
Graft vs Host Disease | 1 | 2015 | 2957 | 0.010 |
Why?
|
Carcinoma, Small Cell | 1 | 1984 | 420 | 0.010 |
Why?
|
Recurrence | 1 | 2013 | 8340 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15076 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 1984 | 2765 | 0.010 |
Why?
|
Cohort Studies | 1 | 2019 | 40561 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20129 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2011 | 6234 | 0.010 |
Why?
|
Mutation | 1 | 2019 | 29786 | 0.010 |
Why?
|
Time Factors | 2 | 2015 | 40075 | 0.010 |
Why?
|
Antineoplastic Agents | 2 | 1984 | 13695 | 0.010 |
Why?
|
Adolescent | 2 | 2011 | 85781 | 0.010 |
Why?
|
Lung | 1 | 1984 | 9856 | 0.000 |
Why?
|
Liver Circulation | 1 | 1984 | 164 | 0.000 |
Why?
|
Perfusion | 1 | 1984 | 1360 | 0.000 |
Why?
|
Colloids | 1 | 1980 | 136 | 0.000 |
Why?
|
Technetium | 1 | 1980 | 334 | 0.000 |
Why?
|
Infusions, Intra-Arterial | 1 | 1980 | 234 | 0.000 |
Why?
|
Sulfur | 1 | 1980 | 166 | 0.000 |
Why?
|
Serum Albumin | 1 | 1980 | 676 | 0.000 |
Why?
|
Radionuclide Imaging | 1 | 1980 | 2031 | 0.000 |
Why?
|
Tissue Distribution | 1 | 1980 | 2327 | 0.000 |
Why?
|
Child | 1 | 2001 | 77709 | 0.000 |
Why?
|
Combined Modality Therapy | 1 | 1984 | 8642 | 0.000 |
Why?
|
Pilot Projects | 1 | 1984 | 8324 | 0.000 |
Why?
|